Despite the promising results of the new treatment and the FDA approval of Seagen and Genmab's tisotumab vedotin for cervical cancer treatment, it is crucial to acknowledge that further research is necessary to comprehensively grasp TF targeted and re-targeted advantages and limitations [317]. This evidence concerns the gene TF and cervical cancer.